


Figure 2: Cost Effectiveness of the Different Treatment Alternatives for Neovascular Macular Degeneration



The figure depicts the total costs and total effectiveness over 20 years with each of the four treatment alternatives. Monthly ranibizumab confers the most costs and the most improvement in quality-adjusted life years whereas as needed bevacizumab confers the least costs and least improvement in quality-adjusted life years. Therapies on the blue line (efficient frontier) are undominated. The ranibizumab as need therapy is dominated by the others (specifically bevacizumab monthly).

QALY= quality-adjusted life years